SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Accounts Payable
SCI Pharmtech Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Accounts Payable
NT$58.4m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-3%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Accounts Payable
NT$644.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Accounts Payable
NT$218.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
5%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Accounts Payable
NT$82.2m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
4%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Accounts Payable
NT$1.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
9%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Accounts Payable
NT$603.1m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Accounts Payable?
Accounts Payable
58.4m
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Accounts Payable amounts to 58.4m TWD.
What is SCI Pharmtech Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
-3%
Over the last year, the Accounts Payable growth was 32%. The average annual Accounts Payable growth rates for SCI Pharmtech Inc have been 20% over the past three years , -9% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet